Does Tirzepatide Affect the Body's Ability to Recover from Low Blood Sugar? | Research

The takeaway

Tirzepatide does not impair the body's hormonal response to low blood sugar in people with type 2 diabetes.

-1.5% HbA1c
Tirzepatide reduced HbA1c by 1.5% while preserving counterregulatory hormone responses

What the researchers found

Tirzepatide 15 mg preserved counterregulatory hormone responses (including glucagon) during induced hypoglycemia, while lowering HbA1c by 1.5%.

Why it matters

Confirming that tirzepatide doesn't blunt the body's defense against low blood sugar is critical for its safety in diabetes management.

The numbers in context

42 participants, crossover design. Tirzepatide 15 mg vs placebo for 12 weeks. HbA1c change: -1.5% vs +0.5%. Nadir PG: 44.5 vs 47.5 mg/dL. Glucagon response not different between groups.

How the study worked

Randomized, placebo-controlled crossover study with hypoglycemic clamp testing in 42 participants over 12 weeks.

Who was studied

Adults with type 2 diabetes

What this study cannot tell us

Only tested 15 mg dose. Crossover design requires adequate washout (8-10 weeks provided). Only type 2 diabetes patients studied.

How to read the evidence

Well-designed randomized crossover study with clamp methodology — strong evidence for this specific safety question.

When this study was published

Published in 2025, providing important post-marketing safety data for tirzepatide.

The bigger picture

This safety data supports tirzepatide use in type 2 diabetes by showing it doesn't increase risk of severe hypoglycemia through impaired counterregulation.

Questions still open

Are counterregulatory responses preserved at lower tirzepatide doses as well?
Does this hold true in patients also taking insulin or sulfonylureas?

Common questions

Does tirzepatide increase the risk of dangerous low blood sugar?

This study found that tirzepatide preserves the body's hormonal responses to low blood sugar, suggesting it does not increase hypoglycemia risk on its own.

What is a hypoglycemic clamp test?

A controlled procedure where blood sugar is deliberately lowered to measure how the body responds with counterregulatory hormones like glucagon.

Read the original research

Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.

Frontiers in endocrinology, 16, 1627947

View on PubMed ↗Publisher’s paper ↗

Citation

Pieber, Thomas R; Svehlikova, Eva; Urva, Shweta; Haupt, Axel; Zhou, Chunmei; Coskun, Tamer; Höller, Vera; Fluhr, Gabriele; Karanikas, Chrisanthi A; Milicevic, Zvonko; Pratt, Edward John. (2025). Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.. Frontiers in endocrinology, 16, 1627947. https://doi.org/10.3389/fendo.2025.1627947